VIDEO: HAWK and HARRIER guides brolucizumab use in nAMD

ByRishi P. Singh, MD

In this video, Rishi P. Singh, MD, staff surgeon at Cleveland Clinic Cole Eye Institute, associate professor of ophthalmology at Lerner College of Medicine, discussed the HAWK and HARRIER study presented at the virtual American Academy of Ophthalmology annual meeting.

Jeff Heier, MD, presented characteristics of patients with and without intraocular inflammation, as well as the efficacy and safety of brolucizumab for patients in the HAWK study.

“Beovu [brolucizumab, Novartis] has been out for the past year now, and we’re looking forward to utilizing this drug for patients ... where it could dry the retina better than other drugs that were currently available,” Singh said. “The problem has been intraocular inflammation. Heier is going to present some of the more interesting characteristics of patients both with and without this inflammation, which may help guide our treatment decisions with this group of patients.”.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview
Heier, J et al. Abstract OPHTHA 11553. Presented at: AAO20 Virtual Scientific Program; Nov 13-15, 2020.

Disclosures: Singh reports he is a consultant to Bausch + Lomb, Novartis, Regeneron and Genentech and receives grant support from Aerie, Apellis and Graybug.

Take Homes in Age-related Macular Degeneration

Read more

VIDEO: HAWK and HARRIER guides brolucizumab use in nAMD

Related Content